Navigation Links
Monsanto Licenses Use of Cellectis' Innovative Genome Modification Technology

ST. LOUIS and ROMAINVILLE, France, Sept. 1, 2009 /PRNewswire-FirstCall/ -- Monsanto Company (NYSE: MON) today announced a non-exclusive research and commercial license agreement with France-based Cellectis S.A. (Alternext: ALCLS), a biotechnology company specialized in genome engineering, for broad use of its meganuclease technology in plants.

Meganucleases are molecular scissors that can be directed to a single site in the genome of a plant cell, thereby allowing a wide range of precise genome modifications, including gene stacking, gene knock-out as well as modulation of gene function to develop new traits. Under the agreement, Monsanto will have access to Cellectis' intellectual property on meganucleases and its custom meganuclease production platform.

Cellectis will receive an upfront payment of euro 3 million, and subject to the approval of the Extraordinary General Meeting of Cellectis' shareholders, Monsanto will make an equity investment of euro 1 million to allow Cellectis to scale the technology for agriculture. Cellectis will also be eligible to receive fees for the development of each meganuclease, success-based milestones and may receive royalties on certain traits commercialized by Monsanto. Further financial details of the agreement were not disclosed.

"Being able to make precise genome modifications could enable us to advance projects even more rapidly through our R&D pipeline," said Robert Fraley, chief technology officer for Monsanto. "This technology has the potential to accelerate delivery of our ever expanding trait pipeline to farmers in the form of value-added, multi-trait products."

"This agreement with Monsanto, the leader in agricultural biotechnology, could allow our meganuclease-based genome engineering technology to be put to use in developing the next generation of quality crops," said Andre Choulika, chief executive officer of Cellectis. "The number of meganuclease users in agricultural biotechnology continues to grow. This agreement confirms our leading position in targeted gene modifications."

About Monsanto Company

Monsanto Company is a leading global provider of technology-based solutions and agricultural products that improve farm productivity and food quality. Monsanto remains focused on enabling both small-holder and large-scale farmers to produce more from their land while conserving more of our world's natural resources such as water and energy. To learn more about our business and our commitments, please visit:

About Cellectis

Cellectis S.A. is a world leader in genome engineering and genome surgery. For more information on Cellectis, visit our website

Cautionary Statements Regarding Forward-Looking Information:

Certain statements contained in this press release are forward-looking statements, such as statements concerning the company's future product performance, regulatory approvals, business and financial plans and other non-historical facts. These statements are based on current expectations and currently available information. However, since these statements are based on factors that involve risks and uncertainties, the company's actual performance and results may differ materially from those described or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, among others: the success of the companies' research and development activities; the costs of and the companies' abilities to access and enforce intellectual property needed for the collaboration; the costs and requirements of regulatory compliance and the speed with which approvals are received; public acceptance of biotechnology products; and other risks and factors detailed in the company's most recent periodic report to the SEC. Undue reliance should not be placed on these forward-looking statements, which are current only as of the date of this presentation. The company disclaims any current intention or obligation to update any forward-looking statements or any of the factors that may affect actual results.

    Contact  Media:  Riddhi Trivedi-St. Clair, Monsanto (314-694-4490)
                     Sylvie Delassus, Cellectis (+331 4183 9900)
                     Caroline Carmagnol, ALIZE RP  (+33 6 64 18 99 59)

SOURCE Monsanto Company
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event
2. Dow AgroSciences, Monsanto Complete U.S. and Canadian Regulatory Authorizations for SmartStax Corn; Plans Set to Launch Seed Platform on 3 Million- to 4 Million-Plus Acres
3. Monsanto, BASF Scientists Disclose Discovery of Gene Conferring Drought Tolerance in Corn Plants
4. Monsantos Historic R&D Investment has Contributed to Mid-20s Gross Profit Growth for Its Seeds and Genomics Segment
5. Monsanto Executives to Discuss Companys Growth Drivers, Profit Goals at Investor Conferences in February
6. BASF and Monsanto Formalize Agreement to Develop Dicamba-Based Formulation Technologies
7. Monsanto Shareowners Reelect Board Members at Companys Annual Meeting
8. Monsanto Board Approves 10 Percent Dividend Increase
9. Monsanto Recognized as Top Biotechnology Employer by Science Magazine
10. Monsanto Sees Growing Opportunity for Biotech Traits Globally
11. New Insect Protection Technology From Monsanto Company Deregulated by USDA
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... Clinovo recently appointed Jeff Parr and ... fast growing clinical data solutions business. , Jeff Parr has spent the past decade ... including Avery Dennison, Thermo Fisher, and Ab Sciex to name a few. He ...
(Date:10/12/2015)... OAKS, Calif. and BRUSSELS , ... UCB (Euronext Brussels: UCB) today presented additional findings from an ... 1 The findings were presented today in an oral ... Research (ASBMR) 2015 Annual Meeting in Seattle ... --> The small exploratory sub-study data ...
(Date:10/12/2015)... -- cell surface marker detection market is ... a new report by Grand View Research, Inc. This growth ... oncology diseases and other cell-associated disorders. --> cell ... 6.49 billion by 2022, according to a new report by ... attributed to rise in incidence of oncology diseases and other ...
(Date:10/12/2015)... offers user-friendly, multi ... --> offers user-friendly, ... online experience --> ... version for enriched online experience Elsevier ... information products and services, announced today that it has ...
Breaking Biology Technology:
(Date:9/24/2015)... Publiceringsförbud fram till: ... Kerv ( ), det Londonbaserade ... första kontaktlösa betalningsring på i ett ... för massproduktion via crowdfunding.       ... Kerv-bärare kan göra direkta kontaktlösa betalningar ...
(Date:9/10/2015)... Report Details The global wearable technology market ... of revenues, consumer adoption and even technological advances. However, ... begin to achieve that mass market acceptance that has ... the entrance of Apple to the SmartWatches market, which ... overall size of the wearable technology market. Visiongain ...
(Date:9/9/2015)... , Sept. 9, 2015  NuData Security ... and solution-based milestones, furthering the company,s commitment to ... online fraud. NuData Security,s online fraud ... the company,s growth cycle. The product combines continual ... determine good user behavior from fraudulent behavior, allowing ...
Breaking Biology News(10 mins):